Stockholders' Equity and Warrants

3 Months Ended

Mar. 31, 2025

Stockholders' Equity Note [Abstract]

Stockholders' Equity and Warrants

Note 10. Stockholders' Equity and Warrants

Common Shares Outstanding and Common Stock Equivalents

The following table shows the number of our common shares that could be issued for each component of our capital structure.

		March 31, 2025	December 31, 2024
Outstanding common shares	(1)	120,149	119,770
Common shares reserved for future issuance:
Private warrants		1,796	1,796
Stock options		3,140	3,181
Restricted and performance stock units and awards (Note 11)		12,882	14,119
2020 Equity Plan pool reserved for future issuance (Note 11)		13,668	7,698
Convertible senior notes, due 2026	(2)	6,950	6,950
Convertible senior notes, due 2028		13,332	13,332
Total shares of common stock outstanding and reserved for future issuance		171,917	166,846

______________________________________

(1)Includes 18.3 million shares of common stock held by the Reciprocal as of March 31, 2025.

(2)In connection with the September 16, 2021, issuance of the 2026 Notes, we used a portion of the proceeds to pay for the capped call transactions, which are expected to generally reduce the potential dilution to our common stock. The capped call transactions impact the number of shares that may be issued by effectively increasing our conversion price from $25 per share to approximately $37.74, which would result in approximately 5 million potentially dilutive shares instead of the shares reported in this table as of March 31, 2025.

Warrants

There was no activity related to private warrants during the three months ended March 31, 2025 and 2024. As of March 31, 2025, and December 31, 2024, there were 1.8 million private warrants outstanding for common shares. The exercise price of these private warrants is $11.50, and they expire on December 23, 2025. The private warrants are liability classified financial instruments measured at fair value, with periodic changes in fair value recognized through earnings and are included in “change in fair value of private warrant liability” in the unaudited Condensed Consolidated Statements of Operations and Comprehensive Income (Loss). See Note 6 for more information.